Event Overview

Discovery on Target is positioned as a leading industry conference focused on novel drug targets and technologies for drug discovery professionals. The event is structured to bring together the science, technology, and people shaping therapeutic innovation across multiple modalities, including small molecules, antibodies, peptides, conjugates, and radiopharmaceuticals.

The conference runs over several days with pre-conference activities on September 28, 2026 and the main modality tracks operating from September 29 through October 1, 2026. It is designed around deep technical education (symposia, training seminars, short courses) plus a conference program that supports collaboration through presentations, exhibits, posters, and interactive sessions.

Official Event Facts (from provided source)

• Dates: September 28 – October 1, 2026
• Venue: (Not stated in the provided website text)
• City: (Not stated in the provided website text)
• Country: (Not stated in the provided website text)
• Event type: Drug discovery conference focused on target discovery, lead generation, screening technologies, AI/ML, and next-generation biologics
• Theme emphasis: Modality-agnostic and technology-nimble approaches to tackling difficult drug targets

1) Who Attends (Buyers / Attendees)

Discovery on Target is not a general pharma conference; it is technology- and science-centric, which strongly shapes attendee composition. The “buyer” side at events like this typically clusters around teams that influence or purchase technology, services, and enabling capabilities across the drug discovery lifecycle.

Primary attendee groups

• Drug discovery scientists and leaders working on target identification, lead generation, and validation (including platform and translational teams).
• Translational research and early R&D decision-makers who prioritize pipeline creation and investment in enabling technologies.
• Computational / data science and AI/ML researchers engaged in design-of-experiments, screening optimization, and target discovery analytics.
• Assay development and screening technology teams supporting functional proteomics, phenotypic modeling, and complex in vitro systems.
• Biologics and radioligand specialists covering antibodies against challenging targets, novel conjugates, and theranostics/dosimetry strategy.
• External solution providers represented via exhibitors and sponsors (e.g., platform vendors, service providers, and enabling technology companies).
• Poster authors and presenting teams whose work aligns to specific tracks such as induced proximity, GPCR-targeted discovery, DEL/FBDD/covalent approaches, and radioligand engineering.

Best “buyer” roles to target (behaviorally)

• Head / Director, Drug Discovery (or early-stage pipeline leadership)
• Director / VP, Target Discovery and Lead Generation
• Program leaders for modality platforms (small molecules, biologics, proximity-inducing, PROTAC/degrader, peptides, conjugates, radioligands)
• Translational Research Leaders coordinating target-to-candidate decisions
• Computational biology / AI/ML leadership influencing tool adoption
• Screening and assay development leadership
• Scientific partnerships / business development for R&D platforms (often critical for vendor evaluation cycles)
• Research operations leaders supporting technology workflows and vendor onboarding

In practical list-building terms, this event tends to attract the scientific buyer layer (people who define technical needs) plus the commercial evaluation layer (people who assess vendors, solutions, and collaborations). That combination is valuable when we build a high-intent buyer list aligned to drug discovery technology purchasing and partnering cycles.

2) Where the Show Is Happening + Attendee Geographic Origin

The provided website text does not state the venue city/country. Because we must not invent facts, we leave location details as not provided.

However, the event’s attendee and speaker footprint indicates broad international participation. Based on the “By the Numbers” section: 22 countries are represented, and the technical content spans widely adopted drug discovery approaches used globally.

Attendee geographic origin (reliable from provided text)

• International mix: Confirmed 22 countries represented.
• Primary driver: Global drug discovery ecosystem and internationally shared platform technologies.

For targeting, we typically recommend building buyer lists with an international lens (EU, UK, US, and other biotech hubs), then weighting by which markets match the client’s sales motion (direct pharma, regional biotech, or global CRO/service partners).

3) Audience Reach (Local / National / Global)

Discovery on Target is best classified as a global reach scientific conference rather than a local or purely national event. The website specifically indicates 22 countries represented, and the breadth of tracks (small molecules, biologics, radioligands, AI/ML, screening technologies, and next-generation modalities) supports worldwide relevance.

• Reach type: Global
• Why: 22 countries represented; international program and speaker mix; modality topics have global R&D adoption

4) Sample Buyer Company Names (BUYERS ONLY) + Websites

Below are buyer-fit sample targets commonly associated with attending or evaluating drug discovery technologies, platforms, and services. These are examples of organizations with drug discovery engines and early R&D teams whose needs align closely with the conference’s themes.

If you share our client product website, we will refine this list to the best-fit buyers for your specific offering (platform, tool, service, assay, data/AI, instrumentation, or enablement).

Note: The table above is a buyer-fit example list. For a precise “best buyers” selection, we need our client’s product details (see point 8 below).

5) Job Profiles, Industries & Event Type

Event type (best-fit classification)

• Drug discovery conference
• Technology and platform showcase (exhibits, posters, interactive sessions)
• Scientific education + networking (symposia, plenary keynote, seminars, short courses)

Job profiles to target

• Chief / VP / Director, Target Discovery
• Chief / VP / Director, Lead Generation and/or Early Discovery
• Head of Screening Technology and Assay Development
• Head of Computational Biology, AI/ML Drug Design, or In Silico Screening
• Director, Biophysics / Biophysical Approaches
• Director, Functional Proteomics (for direct-to-biology applications)
• Director, Library Innovation Programs (DEL/FBDD/Covalent/D2B)
• Director, Proximity-Induced Drug Discovery (including PROTAC/degraders/molecular glue/proximity inducers)
• Director, Biologics Discovery (antibodies against challenging targets)
• Director, Conjugate / Linker Chemistry programs
• Director, Radioligand / Theranostics (optimized ligands, linkers, radionuclides, dosimetry)
• Director, Target Validation / Translational Early R&D
• Scientific Partnership leadership: Scientific Partnerships, Business Development, R&D Alliances

Industry alignment using the provided Apollo-like industry list

The most relevant industries from the provided list for this event are the following (in priority order):

• Pharmaceuticals
• Biotechnology
• Medical Devices (indirect fit if radioligand/theranostics overlaps with device ecosystems)
• Research (especially for institutes and labs with discovery focus)
• Computer Software and Information Technology & Services (for AI/ML, screening platforms, informatics tools)
• Market Research and Management Consulting (only for specialized market/tech strategy roles; secondary fit)
• Events Services (not buyer intent; typically not a primary targeting industry)

We recommend targeting primarily Pharmaceuticals, Biotechnology, Research, and then adding AI/ML software tool industries only if our client product is technology-led rather than biological/assay-led.

6) Estimated Attendance (Expected Total Footfall)

The “By the Numbers” section provides the strongest estimate indicators:

• Attendees: 1,100+ attendees
• Speakers: 250+ speakers
• Presentations: 220+ presentations
• Research posters: 115+ research posters
• Exhibitors: 90 exhibitors

For buyer engagement, the attendee number matters, but the most valuable engagement usually correlates with: (1) attendance of early discovery and platform leaders, and (2) presence of solution providers exhibiting in the relevant modality tracks. We can design targeting criteria so our list prioritizes those roles.

7) Key Focus Areas & Buyer Engagement

Key focus areas (as reflected by the conference structure)

• Novel drug targets and tackling difficult targets
• Target discovery and lead generation across modality types
• AI/ML and generative approaches in drug design and screening tools
• Library innovations (DEL, FBDD, covalent, D2B)
• Proximity-induced strategies including PROTACs/degraders and molecular glues
• Functional proteomics and direct-to-biology applications
• Phenotypic and complex in vitro models
• GPCR-targeted discovery
• Biophysics approaches
• Biologics discovery (antibodies against challenging targets)
• Conjugate/linker chemistry and next-generation targeting/delivery
• Radioligand therapies and theranostics (including dosimetry and optimized ligands/linkers/radionuclides)
• ADME and pharmacokinetics considerations connecting exposure at the target to candidate selection decisions

Buyer engagement opportunities

The event supports engagement through multiple formats: plenary keynotes, panel discussions, symposia, training seminars, short courses, presentations, exhibits, posters, and interactive sessions.

• Technical buyer conversations are best initiated around a specific track (e.g., induced proximity, radioligands, AI/ML screening).
• Partnering and collaboration are stimulated through poster sessions and interactive formats where teams share methods and outcomes.
• Vendor evaluation cycles are often influenced by seminars and short-course education that demonstrates real-world applicability.
• Innovation narrative matters: the conference framing emphasizes a modality-agnostic approach and “technology-nimble” thinking.

For our attendee-list research and buyer targeting, we align messaging to the buyer’s role in decision-making: whether they influence target selection, screening strategy, platform adoption, assay workflows, or translational transition.

8) Client-Product Fit: Best Buyers Based on Our Client Requirement

We can determine the “best buyers” more accurately only after we review the client’s product website and understand: (a) the product category (assay/service/platform/software/instrumentation), (b) the customer type (pharma, biotech, academic labs, CROs), and (c) the specific workflow stage supported (target identification, lead generation, screening, validation, optimization, translational).

What we need from you

• Client product website URL
• Which drug discovery stage it supports (or what problem it solves)
• Whether it is more relevant to small molecules, biologics, proximity/degraders, radioligands, or AI/ML tooling
• Geographic focus (US/EU/APAC) if any

Proposed buyer shortlisting logic (how we will refine)

• If the client product is an AI/ML or screening informatics tool, we will prioritize computational biology, data science, and screening technology leaders.
• If it is target discovery platform or library innovation, we will prioritize target discovery and lead generation directors and program leaders.
• If it is biologics/conjugate/radioligand related, we will prioritize modality-specific leadership and translational evaluation roles.
• If it is a services or CRO-style enablement offering, we will prioritize research operations and platform evaluation decision-makers as well as scientific partnerships leadership.

Please share the client website and we will respond with a refined “best buyers” set and the most relevant job titles to target for this specific offering.

9) Final Recommendation (Buyer-Intent Summary)

Discovery on Target is a strong conference for building high-intent buyer lists in the drug discovery ecosystem because:

• It concentrates on early discovery and target-to-lead problem spaces (target discovery, lead generation, screening, validation).
• The program coverage includes AI/ML, proximity-induced strategies, library innovations, functional proteomics, and next-generation modalities.
• It shows meaningful scale with 1,100+ attendees, 90 exhibitors, and 115+ posters.
• The international presence (22 countries represented) supports global outreach and cross-region buyer engagement.

Our best approach is to align buyer targeting to a client’s offering and to the specific track themes (rather than treating attendees as a generic pharma crowd). Once we review the client website, we will deliver a “best buyers” recommendation that matches the strongest decision-maker roles for that product category.